BIOXYTRAN, INC
BIXT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BIXT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BIXT
Bioxyntran, Inc. is a pre-revenue biotech company focused on drug development, currently conducting preclinical toxicity studies and facing significant financial challenges as a going concern.
Key risk: Going concern uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.7M
Cash Runway
—
Lead Asset
BXT-25 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for BIOXYTRAN, INC.
Similar companies
Bioxyntran, Inc. is a pre-revenue biotech company focused on drug development, currently conducting preclinical toxicity studies and facing significant financial challenges as a going concern.
- As of June 30, 2026, Bioxyntran had an accumulated deficit of $23,733,164 [sec_mda · as of 2026-08-14].
- The company reported a net loss of -$0.6M and negative shareholders' equity of -$2.6M as of June 30, 2026 [latest reported financials].
- Bioxyntran has a convertible loan outstanding at a total face value of $805,000 and total debt of $3,750,156 as of August 2026, including $1,367,713 owed to affiliates [sec_mda · as of 2026-08-14].
- The company is conducting preclinical studies, including a 14-day repeated dose toxicity study in New Zealand Rabbits and Wistar Rats, as funding permits [sec_mda · as of 2026-05-15].
- Management plans to seek additional capital through private placements and public offerings, but there is substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2026-08-14].
What works
- Initial preclinical results showed non-toxicity and full recovery in Swiss Albino mice in a joint venture with NDPD Pharma, Inc., indicating potential for the experimental drug [sec_mda · as of 2026-05-15].
- The company has a defined next step in its development plan: a 14-day repeated dose toxicity study using New Zealand Rabbits and Wistar Rats [sec_mda · as of 2026-05-15].
What to weigh
- Bioxyntran has an accumulated deficit of $23,733,164 as of June 30, 2026, with no indication of revenue from product sales [sec_mda · as of 2026-08-14].
- The company has negative shareholders' equity of -$2.6M and a net loss of -$0.6M as of June 30, 2026 [latest reported financials].
- There is substantial doubt about the company's ability to continue as a going concern, and without additional capital, it may be required to cease operations [sec_mda · as of 2026-08-14].
- The company's future depends on obtaining financing, which is uncertain, and it has limited resources and operating history [sec_mda · as of 2026-05-15].
From the filings
Quoted directly from source documents.
The company has a large accumulated deficit and faces going concern issues.
“the Company had an accumulated deficit of $23,733,164 as at June 30, 2026”
SEC MD&A · August 14, 2026
The company is conducting preclinical studies with positive initial results.
“The initial results are very encouraging because they show the non-toxicity of the experimental drug, along with the corresponding full recovery in Swiss Albino mice”
SEC MD&A · August 14, 2024
The company's survival depends on obtaining additional financing.
“The future of the Company is dependent upon its ability to obtain financing to develop its new business opportunities and support the cost of the drug development including clinical trials and any regulatory submission to the FDA”
SEC MD&A · August 14, 2026
The company has convertible debt and affiliate obligations.
“The remaining debt mounts to $3,750,156 (whereof $1,367,713 is owed to affiliates with an accrued interest of $75,761)”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue; may cease operations without additional capital [sec_mda · as of 2026-08-14]
- Accumulated deficit — Accumulated deficit of $23.7M as of June 2026, with no revenue from operations [sec_mda · as of 2026-08-14]
- Financing dependency — Future depends on raising capital through private placements or public offerings, which is uncertain [sec_mda · as of 2026-08-14]
- Preclinical stage — Drug development is at early preclinical stage; no clinical trials initiated yet [sec_mda · as of 2026-05-15]
What to watch
- Ability to secure additional financing to fund operations and preclinical studies [sec_mda · as of 2026-08-14]
- Progress and results of the planned 14-day repeated dose toxicity study in New Zealand Rabbits and Wistar Rats [sec_mda · as of 2026-05-15]
- Any updates on the joint venture with NDPD Pharma, Inc. [sec_mda · as of 2026-05-15]
- Changes in accumulated deficit and cash position in future filings [sec_mda · as of 2026-08-14]
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run BIOXYTRAN, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIOXYTRAN, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
OCF -$350K · Net income -$620K
Lead: Preclinical
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for BIOXYTRAN, INC?
Bioxyntran, Inc. is a pre-revenue biotech company focused on drug development, currently conducting preclinical toxicity studies and facing significant financial challenges as a going concern.
What is BIOXYTRAN, INC's lead drug candidate?
BIOXYTRAN, INC's most advanced tracked candidate is BXT-25 (Preclinical) for ischemic stroke.
Who is the CEO of BIOXYTRAN, INC?
Dr. David Platt Ph.D. is the chief executive officer of BIOXYTRAN, INC (BIXT).
Where is BIOXYTRAN, INC headquartered?
BIOXYTRAN, INC (BIXT) is headquartered in Needham, MA, United States.
What therapeutic areas does BIOXYTRAN, INC focus on?
BIOXYTRAN, INC develops therapies across Neurology, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.